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Cachexia, a frequent pathophysiological complication of malignancy, is charac-
terized by progressive wasting of adipose and muscle tissues, anorexia, asthenia,
and anemia (1-3). In a portion of cancer patients, wasting can be accounted for by
neoplasticinvasion of the gastrointestinal tract or by toxic injury resulting from che-
motherapy. However, in most cases, the development ofcachexia cannot be correlated
with tumor burden, pathology, anatomic location, or treatment. Alterations in lipid,
protein, and carbohydrate metabolism observed in cancer cachexia (1, 2) are similar
to those detected in major injury or sepsis (4, 5).
Recent attention has focused on the role of TNF/cachectin in the development
of cachexia in neoplastic and infectious disease (6). TNF has numerous biological
activities including suppression of lipoprotein lipase (LPL) activity in adipocytes
(7). Reduced LPL activity in plasma and adipose tissue correlates with, and may
be responsible for, the hyperlipidemia and weight loss that are often observed in
cancer patients (8, 9). Data from two studies support the hypothesis that TNF in-
duces weight loss in cancer cachexia. Treatment of mice with conditioned media
from endotoxin-activated macrophages, which contains TNF, reduces food intake
and weight (10). Recently, we reported that nude mice, with tumors that secrete TNF,
develop cachexia (11) .
We have extended those studies to test whether treatment with recombinant human
TNF (rHuTNF) induces cachexia in normal mice. rHuTNF was administered by
injection twice daily or by implantation of osmotic pumps. Reductions in food in-
take and body weight were induced initially by rHuTNF. However, with continued
treatment, the mice developed a tolerance to rHuTNF and resumed their pretreat-
ment appetite and weight.
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Materials and Methods
BriefDefinitive Report
Mice.
￿
Endotoxin-resistant C3H/HeJ female mice were obtained from theJackson Labo-
ratory, Bar Harbor, ME. Mice weighed 19-23 g and were 8-14 wk old at the time of treat-
ment. Mice were housed six per cage and fed ad libitum. Food intake and body weight were
measured daily.
HuTNF Purification.
￿
rHuTNF, purified from Escherichia coli bearing a plasmid with an
Address Correspondence to Susan H. Socher, Merck Sharp & Dohme Research Laboratories, W16-3,
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F[GURE I.
￿
Clearance of rHuTNF from serum. Mice were
injected intraperitonealy with 25 gg'z'I-rHuTNF and sera
collected at the indicated times. The serum levels ofrHu"I'NF
were quantitated by radioactivity (") and by the radio-
receptor assay (O).
HuTNF gene (12), was >90% pure by SDS-PAGE and had a specific activity of 1-5 x 10'
cytolytic U/mg.
TreatmentofMice with rHuTNF
￿
rHuTNF was administered intraperitonealy by either in-
jection or implantation of osmotic pumps. rHuTNF was injected in 0.5 ml of PBS containing
0.1% BSA. Alzet mini-osmotic pumps (model 2002; Alza Corp., Palo Alto, CA) were filled
with rHuTNF in 0.85% NaCl containing 0.1% BSA; the pumps delivered rHuTNF at a rate
of 0.5 ltl/h. When tested by the Limulus amebocyte lysate assay, rHuTNF at 50 lag/ml in
the injection vehicle, rHuTNF at 1 mg/ml in the pump vehicle, the injection vehicle alone,
and the pump vehicle alone contained 30 .72, 31.13, 30.72, and 29 .76 endotoxin U/ml, respec-
tively.
Iodination of rHuTNF
￿
' 2;1-rHuTNF, radiolabeled by a solid phase lactoperoxidase pro-
cedure (13), had an initial specific activity of 60-200 pCi/ltg and retained >90% of the cyto-
lytic activity of unlabeled rHuTNF.
Serum Levels of rHuTNF
￿
Mice were injected intraperitonealy with 25 wg of'1'I-rHuTNF
that had a specific activity of tit gCi/ltg. Groups ofthree mice were killed and bled at desig-
nated times. rHuTNF in sera was quantitated by counting in a gamma counter and by a
radioreceptor assay (14). Serum was also collected from four mice 24 h after placement of
osmotic pumps that released 12 ug/day of rHuTNE rHuTNF in those sera was measured
by a sandwich ELISA (11) and by the radioreceptor assay.
Results
After intraperitoneal injection ofmice with rHuTNF, serum levels ofradiolabeled
rHuTNF rose quickly, peaked at 3 4g/ml at 2 h, and dropped to 0.69 ltg/ml within
6 h (Fig. 1) . When serum rHuTNF was quantitated by the radioreceptor assay, similar
kinetics were observed, except that the level of biologically active rHuTNF was <50
ng/ml 5 h after injection. Similar results were reported for the clearance of native
mouse TNF from the serum of CD-1 mice after intraperitoneal injection (15). Serum
levels of rHuTNF were 72-148 ng/ml 24 h after placement of pumps that released
12 gg rHuTNF/day.
We next looked at the effects ofrHuTNF on appetite and body weight. Injections
of rHuTNF twice a day caused a greater reduction in food intake than the same
total dose given as a single injection (data not shown). Next, we tested whether repeated
twice daily intraperitoneal injections of rHuTNF would result in sustained reduc-
tions in appetite and weight . Dose-dependent decreases in food intake and weightSOCHER ET AL . BRIEF DEFINITIVE REPORT
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FIGURE 2 .
￿
Effects of rHuTNF on food intake .
Average food intake of mice (6/group) injected
intraperitonealy twice a day with: PBS containing
0.1% BSA, vehicle control (O) ; 3 pg rHuTNF(x ) ;
12 pg rHuTNF (0) ; 24 pg rHuTNF (" ).
were observed initially (Figs . 2 and 3) . Mice treated with 24 Ag rHuTNF/injection
lost 17% of their pretreatment weight after 4 d of treatment . However, after the ini-
tial reduction, mice increased their food consumption and regained their pretreat-
ment weight in spite of continued twice daily injections ofrHuTNF. Thus, the mice
developed a tolerance to rHuTNF. Doses ofrHuTNF >25 wg twice a day were lethal .
The reductions in food intake and weight observed after treatment with rHuTNF
do not appear to be due to contaminating LPS in the rHuTNF preparations . Similar
levels of endotoxin, i.e., -30 U/ml, were found in the rHuTNF/vehicle and vehicle
preparations . Injection of 10 ug LPS (-1,000 endotoxin units) twice a day did not
reduce food intakeand weight ofendotoxin-resistant mice (data not shown) . Moreover,
injection of 10 gg LPS with 20 gg rHuTNF twice a day did not enhance the reduc-
tions in appetite and weight observed after treatment with rHuTNF alone .
We questioned whether TNF must be present continuously to induce a sustained
weight loss . Continuous intraperitoneal administration of rHuTNF was achieved
by implantation of mini-osmotic pumps . Dose-dependent, biphasic reductions in
food intake (data not shown)and weight (Fig . 4) were observed in mice bearing pumps
FIGURE 3 .
￿
Effects of rHuTNF injected intraperi-
tonealy on body weight. Relative changes in body
weight ofmice (6/group) treated twice daily with :
PBS containing 0.1% BSA, vehicle control (O) ;
3 pg rHuTNF (x) ; 12 pg rHuTNF(0 ) ; 24 pg
rHuTNF(O) .1960
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FIGURE 4 .
￿
Effects ofrHcTNF administered by
intraperitonealy implanted pumps on body weight.
Relative changes in body weight of mice (6/group)
bearing osmotic mini-pumps releasing: 0.85%
NaCl containing 0.1% BSA, vehicle control (O);
0.75 ug rHuTMF/day (x) ; 3 .0 ug rHuTNF/day
(0) ; 12 gg rHuTNF/day (" ) .
that released rHuTNF. The time course of weight loss and regain was similar to
that observed after repeated injections ofrHuTNE Mice that received higher doses
of rHuTNF, i .e ., >-25 ug/day, died within 3 d of placement of the pumps .
Since treatment with a constant daily intraperitoneal dose ofrHuTNF failed to
induce long-term weight loss, we examined the effects ofescalating doses ofrHuTNE
Mice were injected intraperitonealy twice daily with rHuTNF at 12.5 leg/injection
on days 0, 1, and 2 ; at 18.75 ug/injection on day 3 ; at 25 lag/injection on days 4
and 5 ; at 37.5 4g/injection on day 6 ; and at 50 wg/injection on day 7 . Even with
an increase to 50 gg rHuTNF twice a day, the mice regained their pretreatment
appetite and weight .
The observed tolerance to rHuTNF faded within <3 wk ofthe termination of treat-
ment . 17 d after the last injection ofrHuTNF in the escalating dose experiment de-
scribed above, the mice were treated twice a day for 2 d with 25 gg rHuTNF. Com-
parable reductions in food intake and weight were measured in mice that had shown
tolerance to rHuTNF earlier and in mice that had not been previously treated with
rHuTNF.
Discussion
Intraperitoneal administration of rHuTNF induced only short-term reductions
in food consumption and weight in endotoxin-resistant mice in spite of continued
treatment with rHuTNE The mechanism by which rHuTNF causes appetite sup-
pression and weight loss is not known . Semb et al . (16) found that a single in-
traperitoneal dose of 30 gg of recombinant murine TNF suppressed adipose LPL
for at least 48 h . A similar dose ofrHuTNF in our hands had a small effect on food
intake and no measurable effect on weight . It seems unlikely that suppression of
adipose LPL alone is responsible for the weight loss observed here after multiple
injections ofrHuTNE Remick et al . (17) have shown that a single intravenous injec-
tion of TNF had cytopathological effects on the gastrointestinal tract including de-
velopment of a vascular leak syndrome and damage of villi and endothelial cells .
Such damage to the gastrointestinal tractmay account for the suppression and weight
loss observed after treatment of mice with rHuTNF.
The mechanisms that underlie the induction oftolerance to rHuTNF are not defined .SOCHER ET AL. BRIEF DEFINITIVE REPORT
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Several observations indicate it is unlikely that immunological factors contribute to
its development. A similar transitory response was observed when mice were treated
with native mouse TNF (10), which is not likely to be immunogenic in mice. We
detected low levels of antibodies against rHuTNF in only a few mice that developed
resistance to rHuTNE Also, transitory decreases in food intake and weight were
observed when nude mice were treated with rHuTNF (data not shown) . Addition-
ally, the resistance developed rapidly and faded in <3 wk, which is uncharacteristic
of immune-mediated resistance. Early-phase tolerance to endotoxin, which induces
TNF production in vivo (6) and in vitro (7), develops within a few days of treatment,
but fades within a week (18). Similarities exist between early-phase tolerance to en-
dotoxin and tolerance to rHuTNF.
We reported that chronic appetite suppression and weight loss occurred in nude
mice with tumors that secrete rHuTNF (11). That observation contrasts sharply with
the biphasic decreases in food intake and weight in normal mice treated with rHuTNF
reported here. Yet, higher levels of rHuTNF were detected in sera from normal mice
treated with rHuTNF, i .e., almost 3 ug/ml after injection and up to 148 ng/ml in
mice with pumps, compared with 1-23 ng/ml in the tumor-bearing mice. The ability
of rHuTNF to induce anorexia and cachexia may be dependent on the physiologic/dis-
ease status of an animal, and not simply a function ofTNF dose. It is well documented
that neoplastic disease produces a wide range of effects in multiple organ systems.
Moreover, Bartholeyns et al_ (19) recently reported that mice bearing selected solid
tumors showed increased sensitivity to the lethal effects ofendotoxin and TNF. Reso-
lution ofthe apparent dichotomy in the ability ofTNF to induce weight loss in normal
and tumor-bearing mice should help define the role of TNF in the development of
cancer-associated cachexia.
Summary
We examined the effects of treatment with rHuTNF on food consumption and
body weight in C3H/HeJ mice. rHuTNF was administered intraperitonealy either
by injections of 3, 12, or 24 ug twice a day or by implantation of osmotic pumps
that released 0.75, 3, or 12 ug per day. Dose-dependent reductions in both food in-
take and weight were induced by rHuTNF. However, in spite of continued exposure
to rHuTNF, the mice developed a resistance to rHuTNF and resumed their pretreat-
ment food intake and weight . Non-immunological factors may play a role in the
development of this tolerance, since it developed rapidly and faded within 2 wk of
cessation of exposure to rHuTNF.
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the rHuTNF, and Ms. Rita Taylor for assistance in preparation of this manuscript .
Receivedfor publication 19 October 1987 and in revisedform 23 March 1988.
References
1 . Lawson, D. H., A. Richmond, D. W. Nixon, and D. Rudman. 1982. Metabolic approaches
to cancer cachexia. Annu. Rev. Nutr. 2:277.
2. Strain, A. J. 1979. Cancer cachexia in man: a review. Invest. & Cell Pathol. 2:181.
3 . Theologides, A. 1982. Pathogenesis of anorexia and cachexia. Cancer Bull. 34:140.1962
￿
SOCHER ET AL. BRIEF DEFINITIVE REPORT
4 . Brennan, M. F 1977 . Uncomplicated starvation versus cancer cachexia. CancerRes. 37:2359.
5 . Schein, P. S., D. Kisner, D. Haller, M. Blecher, and M . Hamosh. 1979 . Cachexia in
malignancy. Potential role of insulin in nutritional management. Cancer(Phila.). 43:2070 .
6 . Beutler, B., and A. Cerami. 1986. Cachectin and tumor necrosis factor as two sides of
the same biological coin. Nature (Loud.). 320:584.
7 . Beutler, B., J. Mahoney, N. LeTrang, P Pekala, and A. Cerami. 1985 . Purification of
cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW
264.7 cells. J. Exp. Med. 164:984.
8 . Dilman, V. M., L. M. Berstein, M. N. Ostroumova, Y. V. Tsyrlina, and A. G. Golubev.
1981 . Peculiarities of hyperlipidaemia in tumor patients. Br. J Cancer. 43 :637.
9 . Vlassara, H., R. J. Spiegel, D. SanDoval, and A . Cerami. 1986. Reduced plasma lipo-
protein lipase activity in patients with malignancy-associated weight loss. Harm. Metab.
Res. 18:698 .
10. Cerami, A., Y. Ikeda, N. LeTrang, P. J . Hotez, and B. Beutler. 1985 . Weight loss as-
sociated with an endotoxin-induced mediator from peritoneal macrophages: the role of
cachectin (tumor necrosis factor). Immunol. Lett. 11 :173 .
11 . Oliff, A., D. DefeoJones, M. Boyer, D. Martinez, D. Kiefer, G. Vuocolo, A . Wolfe, and
S. H. Socher. 1987 . Tumors secreting human TNF/cachectin induce Cachexia in mice.
Cell. 50:555.
12 . Berent, S. L., R. M . Torczyaski, and A. P Bollon. 1986. Sendai virus induces high levels
oftumor necrosis factor mRNA in human peripheral blood leukocytes. Nucleic Acids Res.
14:8997.
13 . Baglioni, C., S. McCandless, J. Tavernier, and W. Fiers. 1985. Binding of human tumor
necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to
growth inhibition. J. Biol. Chem. 260 :13395.
14. Socher, S. H., M. W. Riemen, D. Martinez, A. Friedman, J . Tai, J . C. Quintero, V.
Garsky, and A. Oliff. 1987. Antibodies against amino acid residues 1-15 of tumor necrosis
factor block its binding to cell-surface receptor. Proc. Natl. Acad. Sci. USA . 84 :8829.
15 . Flick, D. A ., and G. E. Gifford, 1986. Pharmacokinetics of murine tumor necrosis factor.
J. Immunopharmacol. 8:89.
16. Semb, H ., J . Peterson, J . Tavernier, and T Olivecrona. 1987. Multiple effects of tumor
necrosis factor on lipoprotein lipase in vivo. f. Biol. Chem. 262 :8390.
17. Remick, D. G., R. G. Kunkel, J . W. Larrick, and S. L. Kunkel. 1987. Acute in vivo
effects of human recombinant tumor necrosis factor. Lab. Invest. 56:583 .
18. Greisman, S. E., and R. B. Hornick. 1976. Endotoxin tolerance. In The Role of Im-
munologic Factors in Infectious, Allergic, and Autoimmune Processes. R. F. Beers and
E . G. Bassett, editors. Raven Press, New York, 43-50.
19. Bartholeyns, J., M. Freudenberg, and C. Galanos. 1987. Growing tumors induce hyper-
sensitivity to endotoxin and tumor necrosis factor. Infect. Immun. 55 :2230.